Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium

Biomedicine and Pharmacotherapy

Volumn 66, Issue 8, 2012, Pages 607-611

  Yang, Xinxin ^a  

^a JINING MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Buthionine sulfoximine; Caspase 3; Laryngeal squamous cell carcinoma; Mitochondrial membrane potential; N acetyl L cysteine; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; BORTEZOMIB; BUTHIONINE SULFOXIMINE; CASPASE 3; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; COMPETITIVE INHIBITION; ENZYME ACTIVITY; LARYNX SQUAMOUS CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LARYNGEAL NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEASOME INHIBITORS; PYRAZINES; REACTIVE OXYGEN SPECIES;

EID: 84869869656     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.08.010     Document Type: Article

References (50)

1. Li Y., Li F., Li-Ling J., Wang X., Xu Z., Sun K. STK15 gene overexpression, centrosomal amplification, and chromosomal instability in the absence of STK15 mutations in laryngeal carcinoma. Cancer Invest 2005, 23:660-664.
2. Shen Z., Zhan G., Ye D., Ren Y., Cheng L., Wu Z., et al. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol 2012, [In press].
3. Hunter K.D., Parkinson E.K., Harrison P.R. Profiling early head and neck cancer. Nat Rev Cancer 2005, 5:127-135.
4. Chin D., Boyle G.M., Porceddu S., Theile D.R., Parsons P.G., Coman W.B. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 2006, 6:1111-1118.
5. Chen D., Frezza M., Schmitt S., Kanwar J., Dou Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011, 11:239-253.
6. Putzer D., Gabriel M., Kroiss A., Madleitner R., Eisterer W., Kendler D., et al. First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib. Clin Nucl Med 2012, 37:539-544.
7. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
8. Fujita T., Doihara H., Washio K., Ino H., Murakami M., Naito M., et al. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs 2007, 18:677-686.
9. Bae S.H., Ryoo H.M., Kim M.K., Lee K.H., Sin J.I., Hyun M.S. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol Rep 2008, 19:1027-1032.
10. Nawrocki S.T., Sweeney-Gotsch B., Takamori R., McConkey D.J. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004, 3:59-70.
11. Chen K.F., Yeh P.Y., Yeh K.H., Lu Y.S., Huang S.Y., Cheng A.L. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2008, 68:6698-6707.
12. Dick L.R., Fleming P.E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010, 15:243-249.
13. Milano A., Iaffaioli R.V., Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours?. Eur J Cancer 2007, 43:1125-1133.
14. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999, 59:2615-2622.
15. Perez-Galan P., Roue G., Villamor N., Montserrat E., Campo E., Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107:257-264.
16. Jones M.D., Liu J.C., Barthel T.K., Hussain S., Lovria E., Cheng D., et al. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res 2010, 16:4978-4989.
17. Bruning A., Burger P., Vogel M., Rahmeh M., Friese K., Lenhard M., et al. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Invest New Drugs 2009, 27:543-551.
18. Williams S., Pettaway C., Song R., Papandreou C., Logothetis C., McConkey D.J. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003, 2:835-843.
19. Hong Y.S., Hong S.W., Kim S.M., Jin D.H., Shin J.S., Yoon D.H., et al. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1. Int J Oncol 2012, 41:76-82.
20. Teicher B.A., Ara G., Herbst R., Palombella V.J., Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999, 5:2638-2645.
21. Sunwoo J.B., Chen Z., Dong G., Yeh N., Crowl Bancroft C., Sausville E., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001, 7:1419-1428.
22. Lin Y.C., Chen K.C., Chen C.C., Cheng A.L., Chen K.F. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol 2012, 48:585-593.
23. Davis N.B., Taber D.A., Ansari R.H., Ryan C.W., George C., Vokes E.E., et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004, 22:115-119.
24. Papandreou C.N., Daliani D.D., Nix D., Yang H., Madden T., Wang X., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108-2121.
25. Shah M.H., Young D., Kindler H.L., Webb I., Kleiber B., Wright J., et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004, 10:6111-6118.
26. Tsujimoto Y., Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 2007, 12:835-840.
27. Scatena R. Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation. Adv Exp Med Biol 2012, 942:287-308.
28. Yu C., Rahmani M., Dent P., Grant S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 2004, 295:555-566.
29. Ohshima-Hosoyama S., Davare M.A., Hosoyama T., Nelon L.D., Keller C. Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma. J Neurooncol 2011, 105:475-483.
30. Fribley A., Zeng Q., Wang C.Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004, 24:9695-9704.
31. Ling Y.H., Liebes L., Zou Y., Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003, 278:33714-33723.
32. Zimmermann K.C., Bonzon C., Green D.R. The machinery of programmed cell death. Pharmacol Ther 2001, 92:57-70.
33. Zou H., Yang R., Hao J., Wang J., Sun C., Fesik S.W., et al. Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. J Biol Chem 2003, 278:8091-8098.
34. Wang I.K., Lin-Shiau S.Y., Lin J.K. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 1999, 35:1517-1525.
35. He L., Nan M.H., Oh H.C., Kim Y.H., Jang J.H., Erikson R.L., et al. Asperlin induces G(2)/M arrest through ROS generation and ATM pathway in human cervical carcinoma cells. Biochem Biophys Res Commun 2011, 409:489-493.
36. Poyton R.O., Ball K.A., Castello P.R. Mitochondrial generation of free radicals and hypoxic signaling. Trends Endocrinol Metab 2009, 20:332-340.
37. Scatena R., Bottoni P., Botta G., Martorana G.E., Giardina B. The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol 2007, 293:C12-C21.
38. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev 2010, 9:447-464.
39. Armstrong J.S. Mitochondria: a target for cancer therapy. Br J Pharmacol 2006, 147:239-248.
40. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001, 15:2922-2933.
41. Chen C.Y., Liu T.Z., Liu Y.W., Tseng W.C., Liu R.H., Lu F.J., et al. 6-shogaol (alkanone from ginger) induces apoptotic cell death of human hepatoma p53 mutant Mahlavu subline via an oxidative stress-mediated caspase-dependent mechanism. J Agric Food Chem 2007, 55:948-954.
42. Tinhofer I., Bernhard D., Senfter M., Anether G., Loeffler M., Kroemer G., et al. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. Faseb J 2001, 15:1613-1615.
43. Khan M., Ding C., Rasul A., Yi F., Li T., Gao H., et al. Isoalantolactone induces reactive oxygen species mediated apoptosis in pancreatic carcinoma PANC-1 cells. Int J Biol Sci 2012, 8:533-547.
44. Qi X.F., Kim D.H., Yoon Y.S., Kim S.K., Cai D.Q., Teng Y.C., et al. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol Lett 2010, 199:277-287.
45. Liu H., Peng H., Ji Z., Zhao S., Zhang Y., Wu J., et al. Reactive oxygen species-mediated mitochondrial dysfunction is involved in apoptosis in human nasopharyngeal carcinoma CNE cells induced by Selaginella doederleinii extract. J Ethnopharmacol 2011, 138:184-191.
46. Simons A.L., Ahmad I.M., Mattson D.M., Dornfeld K.J., Spitz D.R. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 2007, 67:3364-3370.
47. Arrick B.A., Griffith O.W., Cerami A. Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis. J Exp Med 1981, 153:720-725.
48. Bailey H.H. L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 1998, 111-112:239-254.
49. You B.R., Park W.H. Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase. Toxicol In Vitro 2010, 24:1356-1362.
50. Park W.H., Kim S.H. Involvement of reactive oxygen species and glutathione in gallic acid-induced human umbilical vein endothelial cell death. Oncol Rep 2012, 28:695-700.